Sara Ricardo

List of Publications by Year
in descending order

39 papers	1,594 citations	377584 21 h-index	388640 36 g-index
40 all docs	40 docs citations	40 times ranked	3341 citing authors

#	Article	IF	Citations
1	Mesothelin Expression Is Not Associated with the Presence of Cancer Stem Cell Markers SOX2 and ALDH1 in Ovarian Cancer. International Journal of Molecular Sciences, 2022, 23, 1016.	1.8	2
2	InfectionCMA: A Cell MicroArray Approach for Efficient Biomarker Screening in In Vitro Infection Assays. Pathogens, 2022, 11, 313.	1.2	4
3	Searching for SARS-CoV-2 in Cancer Tissues: Results of an Extensive Methodologic Approach based on ACE2 and Furin Expression. Cancers, 2022, 14, 2582.	1.7	4
4	Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein. Frontiers in Oncology, 2021, 11, 752127.	1.3	9
5	Regulation of invasion and peritoneal dissemination of ovarian cancer by mesothelin manipulation. Oncogenesis, 2020, 9, 61.	2.1	30
6	Recycling the Purpose of Old Drugs to Treat Ovarian Cancer. International Journal of Molecular Sciences, 2020, 21, 7768.	1.8	18
7	Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment. Expert Review of Anticancer Therapy, 2018, 18, 177-186.	1.1	31
8	Mucins and Truncated O-Glycans Unveil Phenotypic Discrepancies between Serous Ovarian Cancer Cell Lines and Primary Tumours. International Journal of Molecular Sciences, 2018, 19, 2045.	1.8	22
9	A Mouse Intra-Intestinal Infusion Model and its Application to the Study of Nanoparticle Distribution. Frontiers in Physiology, 2016, 7, 579.	1.3	7
10	Prognostic significance of CD44v6, p63, podoplanin and MMPâ€9 in oral squamous cell carcinomas. Oral Diseases, 2016, 22, 303-312.	1.5	28
11	Effect of MUC1/Î²-catenin interaction on the tumorigenic capacity of pancreatic CD133+ cells. Oncology Letters, 2016, 12, 1811-1817.	0.8	10
12	Mucin carriers of TF in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2016, 142, 1867-1868.	1.2	1
13	Mucins MUC16 and MUC1 are major carriers of SLea and SLex in borderline and malignant serous ovarian tumors. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2016, 468, 715-722.	1.4	17
14	Navigatorâ€3, a modulator of cell migration, may act as a suppressor of breast cancer progression. EMBO Molecular Medicine, 2015, 7, 299-314.	3.3	34
15	Detection of glycoâ€mucin profiles improves specificity of MUC16 and MUC1 biomarkers in ovarian serous tumours. Molecular Oncology, 2015, 9, 503-512.	2.1	50
16	A novel monoclonal antibody to a defined peptide epitope in MUC16. Glycobiology, 2015, 25, 1172-1182.	1.3	17
17	Differentiation reprogramming in gastric intestinal metaplasia and dysplasia: role of <scp>SOX</scp>2 and <scp>CDX</scp>2. Histopathology, 2015, 66, 343-350.	1.6	32
18	EMMPRIN Expression in Oral Squamous Cell Carcinomas: Correlation with Tumor Proliferation and Patient Survival. BioMed Research International, 2014, 2014, 1-9.	0.9	36

#	Article	IF	Citations
19	696: Glycoprofiling of serous ovarian tumours is a promising strategy for developing new diagnostic tools. European Journal of Cancer, 2014, 50, S167.	1.3	0
20	Phosphorylated <scp>EGFR</scp> at tyrosine 1173 correlates with poor prognosis in oral squamous cell carcinomas. Oral Diseases, 2014, 20, 178-185.	1.5	22
21	OP052. Oral Oncology, 2013, 49, S25.	0.8	0
22	Pâ€cadherin functional role is dependent on Eâ€cadherin cellular context: a proof of concept using the breast cancer model. Journal of Pathology, 2013, 229, 705-718.	2.1	68
23	Phosphorylated mammalian target of rapamycin is associated with an adverse outcome in oral squamous cell carcinoma. Oral Surgery, Oral Medicine, Oral Pathology and Oral Radiology, 2013, 115, 638-645.	0.2	29
24	488 TAp63 Counteracts Invasive and Stem Cell Properties Mediated by P-cadherin in Breast Cancer Cells. European Journal of Cancer, 2012, 48, S117-S118.	1.3	0
25	Pâ€Cadherin Is Coexpressed with CD44 and CD49f and Mediates Stem Cell Properties in Basalâ€like Breast Cancer. Stem Cells, 2012, 30, 854-864.	1.4	64
26	Cancer stem cell markers in breast neoplasias: their relevance and distribution in distinct molecular subtypes. Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin, 2012, 460, 545-553.	1.4	22
27	Immunohistochemical features of claudin-low intrinsic subtype in metaplastic breast carcinomas. Breast, 2012, 21, 354-360.	0.9	43
28	Claudin expression in breast cancer: high or low, what to expect?. Histology and Histopathology, 2012, 27, 1283-95.	0.5	18
29	Breast cancer stem cell markers CD44, CD24 and ALDH1: expression distribution within intrinsic molecular subtype. Journal of Clinical Pathology, 2011, 64, 937-946.	1.0	483
30	Nottingham Prognostic Index in Triple-Negative Breast Cancer: a reliable prognostic tool?. BMC Cancer, 2011, 11, 299.	1.1	50
31	Expression of Monocarboxylate Transporters 1, 2, and 4 in Human Tumours and Their Association with CD147 and CD44. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-7.	3.0	144
32	514 Co-expression of E- and P-cadherin in breast cancer: role as an invasion suppressor or as an invasion promoter?. European Journal of Cancer, Supplement, 2010, 8, 131-132.	2.2	2
33	Evaluation of HER2 in breast cancer: reality and expectations. Expert Opinion on Medical Diagnostics, 2009, 3, 607-620.	1.6	15
34	HER2 evaluation using the novel rabbit monoclonal antibody SP3 and CISH in tissue microarrays of invasive breast carcinomas. Journal of Clinical Pathology, 2006, 60, 1001-1005.	1.0	42
35	c-KIT and PDGFRA in breast phyllodes tumours: overexpression without mutations?. Journal of Clinical Pathology, 2004, 57, 1075-1079.	1.0	41
36	Bilateral Gonadoblastomas in a Dog with Mixed Gonadal Dysgenesis. Journal of Comparative Pathology, 2004, 130, 229-233.	0.1	16

#	Article	IF	Citations
37	Estimation of hormone receptor status in fine-needle aspirates and paraffin-embedded sections from breast cancer using the novel rabbit monoclonal antibodies SP1 and SP2. Diagnostic Cytopathology, 2003, 29, 207-211.	0.5	48
38	p63 Expression in Solid Cell Nests of the Thyroid: Further Evidence for a Stem Cell Origin. Modern Pathology, 2003, 16, 43-48.	2.9	106
39	P63 Expression in Papillary and Anaplastic Carcinomas of the Thyroid Gland: Lack of an Oncogenetic Role in Tumorigenesis and Progression. Pathology Research and Practice, 2002, 198, 449-454.	1.0	29